Gut check: could your microbiome predict fertility after immunotherapy?
NCT ID NCT07201259
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels and analyze gut bacteria. The goal is to see if differences in gut microbiome composition are linked to better or worse fertility outcomes after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a targeted pill stall advanced sarcomas?
- Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells
- New drug combo aims to shrink Hard-to-Treat tumors